Skip To Main Content
Jian-Ying Xu on Muck Rack

Jian-Ying Xu

As seen in: Memory Studies, JAMA (The Journal of the American Medical Association), Royal Society of Chemistry
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jian-Ying

Contact Jian-Ying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Facile synthesis of compact CdS−CuS heterostructures for optimal CO2−to−syngas photoconversion

|
By Jian-Ying Xu, Xiang-Ji Liu, Han-Nan Huang, Yu-Hang Xu
| Royal Society of Chemistry Verified
Facile synthesis of compact CdS−CuS heterostructures for optimal CO2−to−syngas photoconversion Jian-Ying Xu, Xiang-Ji Liu, Han-Nan Huang, Yu-Hang Xu, Zhou Zhong, Y Li, Raymond J. Zeng, Jian Lü and Rong Cao Abstract Herein, a facile two−step synthetic pathway was developed to construct compact CdS−CuS heterostructures for syngas production via CO2 photoreduction. The photocatalytic activity of CdS−CuS−2 was testified with a syngas yield of ca.
Open in Who Shared Issue with article?

Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy | Cancer Biomarkers | JAMA Network Open | JAMA Network

|
By Jian-Ying Xu, Sun Yat-sen, Feng-Hua Wang
| JAMA (The Journal of the American Medical Association) Verified
Key Points Question Are plasma EBV DNA titers associated with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) receiving anti–programmed cell death 1 (anti–PD-1) monotherapy?
Open in Who Shared Issue with article?

Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer - Xiao-Li Wei, Jian-Ying Xu, De-Shen Wang, Dong-Liang Chen, Chao Ren, Jia-Ning Li, Fe

|
By Xiao-Li Wei, Jian-Ying Xu, De-Shen Wang, Dong-Liang Chen
| Memory Studies
Introduction Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer-related death worldwide.1 Most patients with GC present with advanced or metastatic disease.2,3 Systemic cytotoxic chemotherapy and molecular targeted therapy are current main options for those patients.
Open in Who Shared Issue with article?
See all 4 articles